Cargando…

Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression?

I discuss a very obscure activity of p53, namely suppression of senescence (gerosuppression), which is also manifested as anti-hypertrophic, anti-hypermetabolic, anti-inflammatory and anti-secretory effects of p53. But can gerossuppression suppress tumors?

Detalles Bibliográficos
Autor principal:	Blagosklonny, Mikhail V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2012
Materias:	Research Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433931/ https://www.ncbi.nlm.nih.gov/pubmed/22869016

Ejemplares similares

Gerosuppression in confluent cells
por: Leontieva, Olga V., et al.
Publicado: (2014)

As expected, based on rapamycin-like p53-mediated gerosuppression, mTOR inhibition acts as a checkpoint in p53-mediated tumor suppression
por: Blagosklonny, Mikhail V.
Publicado: (2022)

From rapalogs to anti-aging formula
por: Blagosklonny, Mikhail V.
Publicado: (2017)

Gerosuppression by pan-mTOR inhibitors
por: Leontieva, Olga V., et al.
Publicado: (2016)

One-carbon metabolism: An aging-cancer crossroad for the gerosuppressant metformin
por: Menendez, Javier A., et al.
Publicado: (2013)

Rapamycin, proliferation and geroconversion to senescence
por: Blagosklonny, Mikhail V.
Publicado: (2018)

Gerosuppressant Metformin: less is more
por: Menendez, Javier A., et al.
Publicado: (2011)

Identification of Salvia haenkei as gerosuppressant agent by using an integrated senescence-screening assay
por: Matic, Ivana, et al.
Publicado: (2016)

Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells
por: Blagosklonny, Mikhail V.
Publicado: (2012)

Cholesterol esterification and p53-mediated tumor suppression
por: Li, Youjun, et al.
Publicado: (2023)

Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging
por: Blagosklonny, Mikhail V.
Publicado: (2012)

Yeast-like chronological senescence in mammalian cells: phenomenon, mechanism and pharmacological suppression
por: Leontieva, Olga V., et al.
Publicado: (2011)

DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence
por: Leontieva, Olga V., et al.
Publicado: (2010)

p53 action in apoptosis and senescence
por: Lowe, SW, et al.
Publicado: (2000)

Unmet Expectations: miR-34 Plays No Role in p53-Mediated Tumor Suppression In Vivo
por: Jain, Abhinav K, et al.
Publicado: (2012)

MTOR-driven quasi-programmed aging as a disposable soma theory: Blind watchmaker vs. intelligent designer
por: Blagosklonny, Mikhail V.
Publicado: (2013)

The mystery of the ketogenic diet: benevolent pseudo-diabetes
por: Blagosklonny, Mikhail V.
Publicado: (2019)

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma
por: Hamieh, Lana, et al.
Publicado: (2018)

Rapalogs Target the Endothelium to Set the Stage for Acute Lung Injury
por: Petrache, Irina, et al.
Publicado: (2021)

The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway
por: Korotchkina, Lioubov G., et al.
Publicado: (2010)

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth
por: Koo, Junghui, et al.
Publicado: (2015)

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth
por: Koo, Junghui, et al.
Publicado: (2021)

Components of the human-specific, p53-mediated “kill switch” tumor suppression mechanism are usurped by human tumors, creating the possibility of therapeutic exploitation
por: Nyce, Jonathan
Publicado: (2019)

A conundrum in 3-D genome organization and expression?
por: Pederson, Thoru
Publicado: (2022)

Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential
por: Demidenko, Zoya N., et al.
Publicado: (2009)

While reinforcing cell cycle arrest, rapamycin and Torins suppress senescence in UVA-irradiated fibroblasts
por: Leontieva, Olga V., et al.
Publicado: (2017)

Cell cycle arrest is not senescence
por: Blagosklonny, Mikhail V.
Publicado: (2011)

Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence
por: Chao, Suzan K., et al.
Publicado: (2011)

SOCS1, a novel interaction partner of p53 controlling oncogene-induced senescence
por: Mallette, Frédérick A., et al.
Publicado: (2010)

Variable or variate? A conundrum in pharmacometrics exposure–response models
por: Grisic, Ana‐Marija, et al.
Publicado: (2022)

The conundrum of human immune system “senescence”
por: Pawelec, Graham, et al.
Publicado: (2020)

The role of p53 in reproduction, an unexpected function for a tumor suppressor
por: Hu, Wenwei, et al.
Publicado: (2019)

Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion
por: Leontieva, Olga V., et al.
Publicado: (2014)

Severe cellular stress drives apoptosis through a dual control mechanism independently of p53
por: Wang, Yen-Chun, et al.
Publicado: (2022)

Progeria, rapamycin and normal aging: recent breakthrough
por: Blagosklonny, Mikhail V.
Publicado: (2011)

NCI's provocative questions on cancer: some answers to ignite discussion
por: Blagosklonny, Mikhail V.
Publicado: (2011)

Rapamycin extends life- and health span because it slows aging
por: Blagosklonny, Mikhail V.
Publicado: (2013)

Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions
por: Blagosklonny, Mikhail V.
Publicado: (2012)

M(o)TOR of aging: MTOR as a universal molecular hypothalamus
por: Blagosklonny, Mikhail V.
Publicado: (2013)

Rejuvenating immunity: “anti-aging drug today” eight years later
por: Blagosklonny, Mikhail V.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_uo9a3blhtnubnh21ltl11tdppd